167 related articles for article (PubMed ID: 34319443)
1. Delayed adjuvant imatinib in patients with high risk of recurrence of gastrointestinal stromal tumor after radical surgery: a retrospective cohort study.
Qianyi W; Mei X; Rui Z; Yong W; Yutao W; Xiaoding S; Xiaoting W
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1493-1500. PubMed ID: 34319443
[TBL] [Abstract][Full Text] [Related]
2. Using the recurrence risk score by Joensuu to assess patients with gastrointestinal stromal tumor treated with adjuvant imatinib: A retrospective cohort study.
Tang J; Zhao R; Zheng X; Xu L; Wang Y; Feng L; Ren S; Wang P; Zhang M; Xu M
Medicine (Baltimore); 2018 Jul; 97(29):e11400. PubMed ID: 30024511
[TBL] [Abstract][Full Text] [Related]
3. Development and external validation of a nomogram for individualized adjuvant imatinib duration for high-risk gastrointestinal stromal tumors: A multicenter retrospective cohort study.
Liu R; Wu Y; Gong J; Zhao R; Li L; Wan Q; Lian N; Shen X; Xia L; Shen Y; Xiao H; Wu X; Chen Y; Cen Y; Xu X
Cancer Med; 2022 Aug; 11(16):3093-3105. PubMed ID: 35297216
[TBL] [Abstract][Full Text] [Related]
4. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
Wu X; Li J; Xu W; Gao J; Li Y; Shen L
Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
[TBL] [Abstract][Full Text] [Related]
5. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
6. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H; Eriksson M; Hall KS; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Ballman KV; Leinonen M; DeMatteo RP; Reichardt P
Cancer; 2014 Aug; 120(15):2325-33. PubMed ID: 24737415
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Vincenzi B; Napolitano A; Fiocco M; Mir O; Rutkowski P; Blay JY; Reichardt P; Joensuu H; Fumagalli E; Gennatas S; Hindi N; Nannini M; Spalato Ceruso M; Italiano A; Grignani G; Brunello A; Gasperoni S; De Pas T; Badalamenti G; Pantaleo MA; van Houdt WJ; IJzerman NS; Steeghs N; Gelderblom H; Desar IME; Falkenhorst J; Silletta M; Sbaraglia M; Tonini G; Martin-Broto J; Hohenberger P; Le Cesne A; Jones RL; Dei Tos AP; Gronchi A; Bauer S; Casali PG
Clin Cancer Res; 2022 Apr; 28(8):1672-1679. PubMed ID: 34615721
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and prognostic factors for patients with high-risk gastrointestinal stromal tumors treated with 3-year adjuvant imatinib.
Bang YH; Ryu MH; Kim HD; Lee HE; Kang YK
Int J Cancer; 2022 Nov; 151(10):1770-1777. PubMed ID: 35678337
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy observation on imatinib reintroduction in gastrointestinal stromal tumor with high recurrence risk after imatinib adjuvant therapy failure].
Dong Z; Gao J; Gong J; Li J; Li Y; Wang X; Li Y; Shen L; Li J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1286-1289. PubMed ID: 27928801
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
12. Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H; Wardelmann E; Sihto H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Cameron S; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Nilsson B; Kallio R; Junnila J; Vehtari A; Reichardt P
JAMA Oncol; 2017 May; 3(5):602-609. PubMed ID: 28334365
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant Imatinib Treatment for 5 Years versus 3 Years in Patients with Ruptured Localized Gastrointestinal Stromal Tumor: A Retrospective Analysis.
Kang S; Ryu MH; Bang YH; Kim HD; Lee HE; Kang YK
Cancer Res Treat; 2022 Oct; 54(4):1167-1174. PubMed ID: 34883555
[TBL] [Abstract][Full Text] [Related]
14. Assessing prognostic factors of long-term survival after surgery for colorectal gastrointestinal stromal tumours.
Yang S; Maspero M; Holubar SD; Hull TL; Lightner AL; Valente MA; Gorgun E; Kalady MF; Steele SR; Liska D
Colorectal Dis; 2023 Dec; 25(12):2325-2334. PubMed ID: 37876119
[TBL] [Abstract][Full Text] [Related]
15. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), and Spanish Group for Research on Sarcomas (GEIS)
Casali PG; Le Cesne A; Velasco AP; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Penel N; Hartmann JT; Duffaud F; Goldstein D; Martin-Broto J; Gronchi A; Wardelmann E; Marréaud S; Zalcberg JR; Litière S; Blay JY
Ann Oncol; 2021 Apr; 32(4):533-541. PubMed ID: 33482247
[TBL] [Abstract][Full Text] [Related]
16. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
[TBL] [Abstract][Full Text] [Related]
17. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
18. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial.
DeMatteo RP; Ballman KV; Antonescu CR; Corless C; Kolesnikova V; von Mehren M; McCarter MD; Norton J; Maki RG; Pisters PW; Demetri GD; Brennan MF; Owzar K;
Ann Surg; 2013 Sep; 258(3):422-9. PubMed ID: 23860199
[TBL] [Abstract][Full Text] [Related]
20. The analysis of 3-year adjuvant therapy with imatinib in patients with high-risk molecular profiled gastrointestinal stromal tumors (GIST) treated in routine practice.
Rutkowski P; Ziętek M; Cybulska-Stopa B; Streb J; Głuszek S; Jankowski M; Łopacka-Szatan K; Las-Jankowska M; Hudziec P; Klimczak A; Olesiński T; Świtaj T; Koseła-Paterczyk H; Bylina E; Osuch C
Eur J Surg Oncol; 2021 May; 47(5):1191-1195. PubMed ID: 32826113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
